The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated.
Physicians and patients agree on the importance of sleep for optimal health, but few physicians ask about sleep and patients are often reluctant to discuss sleep problems with clinicians.